Synmosa Biopharma (ROCO:4114) Interest Expense : NT$-58 Mil (TTM As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Synmosa Biopharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Synmosa Biopharma's interest expense for the three months ended in Sep. 2024 was NT$ -14 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was NT$-58 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Synmosa Biopharma's Operating Income for the three months ended in Sep. 2024 was NT$ 188 Mil. Synmosa Biopharma's Interest Expense for the three months ended in Sep. 2024 was NT$ -14 Mil. Synmosa Biopharma's Interest Coverage for the quarter that ended in Sep. 2024 was 13.17. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Synmosa Biopharma Interest Expense Historical Data

The historical data trend for Synmosa Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synmosa Biopharma Interest Expense Chart

Synmosa Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-54.37

-52.82

-51.97

-59.58

-67.26

Synmosa Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-14.88	-14.50	-14.31	-14.51	-14.31

Synmosa Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-58 Mil.

Synmosa Biopharma (ROCO:4114) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Synmosa Biopharma's Interest Expense for the three months ended in Sep. 2024 was NT$-14 Mil. Its Operating Income for the three months ended in Sep. 2024 was NT$188 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was NT$1,739 Mil.

Synmosa Biopharma's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Sep. 2024 )	/	Interest Expense (Q: Sep. 2024 )
	=	-1	*	188.444	/	-14.314
	=	13.17

The higher the ratio, the stronger the company's financial strength is.

Synmosa Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synmosa Biopharma Corp (ROCO:4114) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6, Gongye 1st Road, Hukou Township, Hsinchu County, Hsinchu, TWN

Website

https://www.synmosa.com.tw

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

Synmosa Biopharma Headlines

No Headlines